Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$40.91
+1.8%
$45.64
$35.62
$67.66
$2.00B0.85457,510 shs101,182 shs
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$8.98
+0.4%
$10.11
$1.76
$15.21
$869.35M1.144.68 million shs809,783 shs
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
$0.00
-3.8%
$0.00
$0.00
$0.02
$870K-1.413.09 million shs59,990 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$9.05
+0.4%
$9.70
$6.07
$17.02
$529.61M0.63836,052 shs263,632 shs
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$17.83
-1.8%
$20.41
$16.90
$36.64
$498.88M1.6216,382 shs109,899 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
+0.40%-1.50%-8.08%-27.56%-8.37%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-1.76%-11.40%-6.97%+113.37%-35.22%
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
-4.58%-21.88%-26.47%-64.79%-84.33%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
+0.45%-10.08%-18.24%+27.26%-14.84%
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-1.36%+3.18%-3.04%-29.53%-40.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.8307 of 5 stars
3.31.00.03.72.84.23.8
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
1.628 of 5 stars
3.41.00.00.02.02.50.6
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
1.7726 of 5 stars
3.40.00.00.01.74.20.6
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
1.2906 of 5 stars
0.03.01.72.61.21.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.50
Moderate Buy$66.0061.33% Upside
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.75
Moderate Buy$26.56195.72% Upside
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.75
Moderate Buy$21.33135.73% Upside
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
1.00
SellN/AN/A

Current Analyst Ratings

Latest RDUS, PHAT, ARQT, ENDV, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/19/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
4/12/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
4/11/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
4/10/2024
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/1/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
3/22/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
3/15/2024
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
3/5/2024
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$60.00
2/28/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.00
2/28/2024
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $16.00
2/28/2024
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
Seaport Res Ptn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$644.40M3.10$4.47 per share9.16$13.35 per share3.06
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$59.61M14.58N/AN/A$0.94 per share9.55
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
$140K5.95N/AN/A($0.15) per share-0.02
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$680K778.83N/AN/A($1.27) per share-7.13
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$2.88B0.17$4.00 per share4.46$33.14 per share0.54

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$137.54M$2.5815.869.950.9521.34%26.95%12.27%5/14/2024 (Estimated)
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
-$18.48MN/A0.00N/A-1,717.21%N/A-408.63%N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$201.59M-$3.88N/AN/AN/AN/AN/A-63.40%5/8/2024 (Estimated)
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-$25.79M-$2.28N/A19.59N/A-2.28%-1.73%-0.88%6/25/2024 (Estimated)

Latest RDUS, PHAT, ARQT, ENDV, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/4/2024Q2 2024
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-$1.09-$1.04+$0.05-$0.89$626.35 million$621.06 million    
3/7/2024Q4 2023
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$0.92-$0.80+$0.12-$0.21$0.93 million$0.68 million    
2/28/2024Q4 2023
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.84$0.81-$0.03$0.94$174.90 million$178.11 million
2/27/202412/31/2023
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$0.754.21%N/AN/A N/A

Latest RDUS, PHAT, ARQT, ENDV, and AMPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/1/2024
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
quarterly$0.18753.7%4/19/20244/22/20245/6/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.92
2.17
1.70
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.28
7.08
6.80
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
10.25
10.22
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
0.43
1.96
0.92

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,76148.87 million35.62 millionOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
29696.81 million76.77 millionOptionable
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
1333.04 million314.36 millionNot Optionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
45258.52 million44.42 millionOptionable
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
3,35327.98 million26.39 millionOptionable

RDUS, PHAT, ARQT, ENDV, and AMPH Headlines

SourceHeadline
Radius Recycling (NASDAQ:RDUS) Shares Gap Up to $17.43Radius Recycling (NASDAQ:RDUS) Shares Gap Up to $17.43
marketbeat.com - April 17 at 1:11 PM
Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal DiseasesRadius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
finance.yahoo.com - April 16 at 9:27 AM
Radius Recycling (NASDAQ:RDUS) Shares Up 3.6%Radius Recycling (NASDAQ:RDUS) Shares Up 3.6%
marketbeat.com - April 15 at 4:39 PM
Radius Recycling (NASDAQ:RDUS)  Shares Down 6.9% Radius Recycling (NASDAQ:RDUS) Shares Down 6.9%
marketbeat.com - April 10 at 2:52 PM
Radius Health, Inc. (NASDAQ:RDUS) Q2 2024 Earnings Call TranscriptRadius Health, Inc. (NASDAQ:RDUS) Q2 2024 Earnings Call Transcript
finance.yahoo.com - April 8 at 9:35 AM
Radius Recycling (NASDAQ:RDUS) Is Due To Pay A Dividend Of $0.1875Radius Recycling (NASDAQ:RDUS) Is Due To Pay A Dividend Of $0.1875
uk.finance.yahoo.com - April 7 at 7:50 PM
Radius Recycling declares $0.1875 dividendRadius Recycling declares $0.1875 dividend
seekingalpha.com - April 6 at 2:11 PM
Radius Recycling (NASDAQ:RDUS) Downgraded by StockNews.comRadius Recycling (NASDAQ:RDUS) Downgraded by StockNews.com
marketbeat.com - April 5 at 11:10 PM
Radius Recycling, Inc. (RDUS) Q2 2024 Earnings Call TranscriptRadius Recycling, Inc. (RDUS) Q2 2024 Earnings Call Transcript
seekingalpha.com - April 5 at 10:55 PM
Radius Recycling Inc (RDUS) Q2 2024 Earnings Call Transcript Highlights: Strategic Adjustments ...Radius Recycling Inc (RDUS) Q2 2024 Earnings Call Transcript Highlights: Strategic Adjustments ...
finance.yahoo.com - April 5 at 5:55 PM
Radius Recycling, Inc. (NASDAQ:RDUS) Announces $0.19 Quarterly DividendRadius Recycling, Inc. (NASDAQ:RDUS) Announces $0.19 Quarterly Dividend
marketbeat.com - April 5 at 5:19 PM
Radius Recycling (NASDAQ:RDUS) Announces  Earnings ResultsRadius Recycling (NASDAQ:RDUS) Announces Earnings Results
marketbeat.com - April 5 at 8:23 AM
Radius Recycling Second Quarter 2024 Earnings: EPS Misses ExpectationsRadius Recycling Second Quarter 2024 Earnings: EPS Misses Expectations
finance.yahoo.com - April 5 at 7:50 AM
Radius Recycling Reports Q2 Results; American Battery Awarded Another $40.5 Million; Nexa Prices $600 Million Offering And More: Thursdays Top Mining StoriesRadius Recycling Reports Q2 Results; American Battery Awarded Another $40.5 Million; Nexa Prices $600 Million Offering And More: Thursday's Top Mining Stories
benzinga.com - April 4 at 6:02 PM
Radius Recycling (NASDAQ:RDUS) Hits New 12-Month Low at $17.04Radius Recycling (NASDAQ:RDUS) Hits New 12-Month Low at $17.04
marketbeat.com - April 4 at 1:20 PM
Radius Recycling, Inc. 2024 Q2 - Results - Earnings Call PresentationRadius Recycling, Inc. 2024 Q2 - Results - Earnings Call Presentation
seekingalpha.com - April 4 at 11:56 AM
Stocks Rise Before the Open as Investors Shift Focus to Key U.S. Jobs Data, ECB Minutes on TapStocks Rise Before the Open as Investors Shift Focus to Key U.S. Jobs Data, ECB Minutes on Tap
msn.com - April 4 at 10:59 AM
Radius Recycling: Fiscal Q2 Earnings SnapshotRadius Recycling: Fiscal Q2 Earnings Snapshot
finance.yahoo.com - April 4 at 10:59 AM
Radius Recycling Inc (RDUS) Misses Earnings Predictions with Q2 Fiscal 2024 ResultsRadius Recycling Inc (RDUS) Misses Earnings Predictions with Q2 Fiscal 2024 Results
finance.yahoo.com - April 4 at 10:59 AM
Radius Recycling Reports Second Quarter Fiscal 2024 Financial ResultsRadius Recycling Reports Second Quarter Fiscal 2024 Financial Results
globenewswire.com - April 4 at 8:00 AM
Recycling plant on Darrington Road on fireRecycling plant on Darrington Road on fire
kvia.com - March 28 at 12:29 PM
Analysts Estimate Radius Recycling (RDUS) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Radius Recycling (RDUS) to Report a Decline in Earnings: What to Look Out for
zacks.com - March 28 at 11:00 AM
RDUS Sep 2024 30.000 callRDUS Sep 2024 30.000 call
finance.yahoo.com - March 20 at 10:47 PM
RDUS May 2024 30.000 callRDUS May 2024 30.000 call
finance.yahoo.com - March 20 at 12:45 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

NASDAQ:AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Arcutis Biotherapeutics logo

Arcutis Biotherapeutics

NASDAQ:ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Endonovo Therapeutics logo

Endonovo Therapeutics

OTCMKTS:ENDV
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Phathom Pharmaceuticals logo

Phathom Pharmaceuticals

NASDAQ:PHAT
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Radius Recycling logo

Radius Recycling

NASDAQ:RDUS
Radius Recycling, Inc. recycles ferrous and nonferrous metal, and manufactures finished steel products worldwide. The company acquires, processes, and recycles salvaged vehicles, rail cars, home appliances, industrial machinery, manufacturing scrap, and construction and demolition scrap. It offers recycled ferrous metal, a feedstock used in the production of finished steel products; and nonferrous products, including mixed metal joint products recovered from the shredding process, such as zorba, zurik, aluminum, copper, stainless steel, nickel, brass, titanium, lead, and high temperature alloys. The company also procures salvaged vehicles and sells serviceable used auto parts from these vehicles through its retail self-service auto parts stores. In addition, it produces various finished steel products using ferrous recycled metal and other raw materials, as well as semi-finished goods, which include billets; and finished goods consisting of rebar, coiled rebar, wire rods, merchant bars, and other specialty products. Further, the company sells catalytic converters to specialty processors that extract the nonferrous precious metals, including platinum, palladium, and rhodium; and ferrous and nonferrous recycled metal products to steel mills, foundries, refineries, smelters, wholesalers, and recycled metal processors, as well as finished steel customers, such as steel service centers, construction industry subcontractors, steel fabricators, wire drawers, and major farm and wood products suppliers. It also provides recycling and related services, including scrap brokerage, certified destruction, automotive parts recycling, railcar dismantling, and reverse logistics under 3PR brand name. Radius Recycling, Inc. was formerly known as Schnitzer Steel Industries, Inc. and changed its name to Radius Recycling, Inc. in January 2024. Radius Recycling, Inc. was founded in 1906 and is headquartered in Portland, Oregon.